Technology area: Biotechnology & Pharmaceuticals
48 pending office actions • 30 art units • 47 examiners • 0 of 48 (0%) have an AI response strategy ready • 47 patents granted in the last 365 days
City of Hope has 47 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 46 distinct examiners and 29 distinct art units, creating a prosecution program spread across many examiner relationships and examination groups. The difference between the pending-action volume and examiner count indicates that at least some examiner assignments contain more than one current matter, while the art-unit distribution adds another layer of coordination.
BELYAVSKYI, MICHAIL A is the busiest examiner, with 2 pending matters. That is the largest reported individual examiner assignment, but it represents only a limited portion of the overall docket. Counsel should use centralized tracking for deadlines and recurring biotechnology or pharmaceutical positions, while preserving application-specific analysis for the many examiner and art-unit contexts.
Based on the USPTO statutory response window for each pending office action. 24 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 24 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 13 (27%) |
| §102 only | 3 (6%) |
| §112 only | 5 (10%) |
| Double-patenting + other | 8 (17%) |
| Multi-statute (no §101) | 19 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 2 | 63.9% | +28.0% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.4% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279581 | MUC16 PROMOTER CONTAINING VIRUS | ALAM, DANYAL HASSAN | 32d overdue |
| 18255503 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) | CESARE, JOSEPH DAVID | 8d overdue |
| 17976670 | NASAL SWAB | KREMER, MATTHEW | 3d overdue |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 9d |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 12d |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 15d |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | KLINKEL, KORTNEY L | 28d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 28d overdue |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18816718 | T CELLS FOR EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | POPA, ILEANA | — |
| 18757218 | MULTI-SPECIFIC LIGAND BINDERS | PAK, MICHAEL D | — |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | — |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | — |
| 18711088 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS | WANG, RUIXUE | — |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1672 | 4 |
| 1675 | 4 |
| 1633 | 3 |
| 1644 | 3 |
| 1638 | 2 |
| 1635 | 2 |
| 1645 | 2 |
| 1632 | 2 |
| 1642 | 2 |
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18816718 | T CELLS FOR EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18757218 | MULTI-SPECIFIC LIGAND BINDERS | PAK, MICHAEL D | 1674 | §102DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | 1638 | §102 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | 1672 | §102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18711073 | SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES | CHESTNUT, BARRY A | 1672 | §102§103§112DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18711088 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 1635 | §102§103 | Non-Final OA | 29d | Pending | May 02, 2024 |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | 1645 | §102§112Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | 1647 | §103 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18567094 | COMPOSITIONS AND METHODS FOR ISLET CELL TRANSPLANTS | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18288692 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | 1626 | §103DP | Final Rejection | — | Pending | Oct 27, 2023 |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 1632 | §102Other | Final Rejection | 21d | Pending | Oct 17, 2023 |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | MEYERING, SHABANA SHABBEER | 1635 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 1642 | §103§112 | Final Rejection | 9d | Pending | Sep 27, 2023 |
| 18548677 | T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE | CHASE, CAROL ANN | 1646 | §103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18279581 | MUC16 PROMOTER CONTAINING VIRUS | ALAM, DANYAL HASSAN | 1672 | §103§112 | Final Rejection | 32d overdue | Pending | Aug 30, 2023 |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | 28d overdue | Pending | Aug 15, 2023 |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | KLINKEL, KORTNEY L | 1627 | §102§103§112 | Non-Final OA | 28d | Pending | Jul 28, 2023 |
| 18220070 | PREVENTION OR TREATMENT OF WASTING SYNDROME | GROOMS, TIFFANY NICOLE | 1637 | §112 | Non-Final OA | 2d overdue | Pending | Jul 10, 2023 |
| 18266443 | COMPOSITIONS AND USES OF CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | 70d | Pending | Jun 09, 2023 |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 1633 | §102§103 | Non-Final OA | 12d | Pending | Jun 06, 2023 |
| 18255503 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) | CESARE, JOSEPH DAVID | 1675 | §102§103§112 | Final Rejection | 8d overdue | Pending | Jun 01, 2023 |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | FAUST, AMBER KATHLEEN | 1643 | §103DP | Final Rejection | 42d overdue | Pending | May 23, 2023 |
| 18033777 | ENGINEERED NK CELLS | HAM, JIEUN | 1643 | §102§103Other | Non-Final OA | 56d | Pending | Apr 25, 2023 |
| 18032201 | HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES | AL-AWADI, DANAH J | 1615 | §103§112DP | Final Rejection | 66d overdue | Pending | Apr 17, 2023 |
| 18296224 | TREATMENT OF CANAVAN DISEASE | TAKENAKA, RISA | 1632 | §112 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 1644 | §103§112 | Non-Final OA | 15d | Pending | Mar 14, 2023 |
| 18022708 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | CRAIG, KAILA ANGELIQUE | 1618 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18042434 | LAMP DETECTION OF SARS-COV-2 IN SALIVA FOR THE RAPID DIAGNOSIS OF COVID-19 | SWITZER, JULIET CAROLINE | 1682 | §103 | Final Rejection | 23d overdue | Pending | Feb 21, 2023 |
| 18020858 | COMPOSITIONS AND USES OF SARS-COV-2 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED NK CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18017982 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | MARTINEZ, TARA L | 1654 | §103Other | Final Rejection | 29d | Pending | Jan 25, 2023 |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | MACFARLANE, STACEY NEE | 1675 | §103 | Non-Final OA | 36d overdue | Pending | Jan 24, 2023 |
| 18066132 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §112 | Final Rejection | 50d overdue | Pending | Dec 14, 2022 |
| 18073397 | 3 FLAP OKAZAKI FRAGMENTS AND USES THEREOF | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Final Rejection | — | Pending | Dec 01, 2022 |
| 17998469 | COMPOSITIONS AND METHODS FOR BASE SPECIFIC MITOCHONDRIAL GENE EDITING | WHITEMAN, BRIAN A | 1636 | §103 | Non-Final OA | — | Pending | Nov 10, 2022 |
| 17998011 | METHODS FOR ORGANOIDS PRODUCTION | MARCHESCHI, MICHAEL A | 1796 | §102§103§112 | Non-Final OA | — | Pending | Nov 04, 2022 |
| 17976670 | NASAL SWAB | KREMER, MATTHEW | 3791 | §103§112 | Non-Final OA | 3d overdue | Pending | Oct 28, 2022 |
| 17997351 | TAGGED GENE EDITING TECHNOLOGY FOR CLINICAL CELL SORTING AND ENRICHMENT | PYLA, EVELYN Y | 1633 | §103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | QIAN, CELINE X | 1637 | §103§112DP | Final Rejection | 217d overdue | Pending | Sep 14, 2022 |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 9d overdue | Pending | Sep 09, 2022 |
| 17870024 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17843073 | ACCESS NEEDLE SYSTEMS AND METHODS | LI, JOHN DENNY | 3798 | §103 | Non-Final OA | 29d | Pending | Jun 17, 2022 |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DPOther | Non-Final OA | — | Pending | Apr 07, 2022 |
| 17520402 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN | HINES, JANA A | 1645 | §103 | Final Rejection | 110d overdue | Pending | Nov 05, 2021 |
| 17184987 | Surgical Gauze | ARBLE, JESSICA R | 3781 | §102 | Non-Final OA | 26d | Pending | Feb 25, 2021 |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | CONNORS, ALEXANDRA F | 1634 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 16604151 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | LEE, ANDREW P | 1691 | §112 | Final Rejection | — | Pending | Oct 09, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCity of Hope has 48 pending office actions as of October 2026, spread across 30 art units and 47 examiners.
Michail A Belyavskyi has the most, with 2 of City of Hope's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
